Marta G. Walsh

Marta G. Walsh

Auto-generated profile, based on publicly available information

Marta G. Walsh

Department of Pharmaceutical Outcomes & Policy, College of Pharmacy University of Florida Gainesville Florida USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
SSSteven M Smith
Steven M Smith
AWAlmut G. Winterstein
Almut G. Winterstein
MGMatthew Gurka
Matthew Gurka
MWMarta G. Walsh
Marta G. Walsh
SKShailina Keshwani
Shailina Keshwani
RCRhonda M Cooper-Dehoff
Rhonda M Cooper-Dehoff
Background: Knowledge of real‐world antihypertensive use is limited to prevalent hypertension, limiting our understanding of how treatment evolves and its contribution to persistently poor blood pressure control. We sought to characterize antihypertensive initiation among new users. Methods and Results: Using Medicaid and Medicare data from the OneFlorida+ Clinical Research Consortium, we identified new users of ≥1 first‐line antihypertensives (angiotensin‐converting enzyme inhibitor, calcium channel blocker, angiotensin receptor blocker, thiazide diuretic, or β‐blocker) between 2013 and 2021 among adults with diagnosed hypertension, and no antihypertensive fill during the prior 12 months. We evaluated initial antihypertensive regimens by class and drug overall and across study years and examined variation in antihypertensive initiation across demographics (sex, race, and ethnicity) and comorbidity (chronic kidney disease, diabetes, and atherosclerotic cardiovascular disease). We identified 143 054 patients initiating 188 995 antihypertensives (75% monotherapy; 25% combination therapy), with mean age 59 years and 57% of whom were women. The most commonly initiated antihypertensive class overall was angiotensin‐converting enzyme inhibitors (39%) followed by β‐blockers (31%), calcium channel blockers (24%), thiazides (19%), and angiotensin receptor blockers (11%). With the exception of β‐blockers, a single drug accounted for ≥75% of use of each class. β‐blocker use decreased (35%–26%), and calcium channel blocker use increased (24%–28%) over the study period, while initiation of most other classes remained relatively stable. We also observed significant differences in antihypertensive selection across demographic and comorbidity strata. Conclusions: These findings indicate that substantial variation exists in initial antihypertensive prescribing, and there remain significant gaps between current guideline recommendations and real‐world implementation in early hypertension care.

15 March 2023 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
SVScott M. Vouri
Scott M. Vouri
EMEarl J. Morris
Earl J. Morris
MWMarta Walsh
Marta Walsh
JAJessica Agalliu
Jessica Agalliu
ADAlyssa Dempsey
Alyssa Dempsey
SSSteven M Smith
Steven M Smith